3 rd Announcement - 2011 International Conference on Diabetes ...

Session overview
Plenary lecture I
Friday 11 NOV. (10:30~11:10)
The diabetic foot in <strong>2011</strong>
Andrew J. M. Boulton
(University of Manchester, UK)
Prof. Andrew James Michael Boulton is currently a professor at University of
Manchester and University of Miami. His academic interest has been in the areas of
complications of diabetes, particularly the diabetic foot disease and diabetic
nephropathy. He has written over 400 articles and participated as a co-author of 8
relevant books. Professor Boulton was the editor of the "Diabetic Medicine" from 1991
to 1995. After serving as a president of the "Diabetic Foot Study Group" of EASD and the
"Foot Wound Interest Group" of ADA, he is now a vice-president of EASD. At this
symposium, Professor Boulton will give a presentation on recent research trends,
changes in treatment and prospects on diabetic foot disease with a title of “An update
on the diabetic foot for <strong>2011</strong>.”
Plenary lecture II
Satu<strong>rd</strong>ay 12 NOV. (14:00~15:00)
Systemic impact of adipocyte-derived factors: impact on
hepatic physiology
Philipp E. Scherer
(UT Southwestern Medical Center, USA)
Prof. Philipp Scherer is a director of Touchstone Diabetes Center, UT Southwestern
Medical center. As a worldwide leading scientist, Dr. Scherer has been working on the
integrated physiology of the adipocyte and the impact on whole body energy
homeostasis, inflammation and cancer. He is one of pioneers to identify adipocytederived
factors (adipokines) and adipocyte physiology. Especially, he has cloned
“adiponectin” and has elucidated the downstream signaling of adiponectin in the
regulation of carbohydrate and lipid metabolism. Recently, his research team has
demonstrated that adiponectin also plays a role in cancer cell growth and survival. In
this presentation, he will discuss the impact of adipokines on liver physiology.
Special lecture
Friday 11 Nov. (11:10~11:40)
New agents in development for therapy of type 2 diabetes
Robert R. Henry
(University of Califormina, San Diego, USA)
Robert R. Henry is now a professor of Medicine and Division of Endocrinology &
Metabolism at University of California, San Diego.
And he is also currently a President of American Diabetes Association and Science and
is a member of the European Association for the Study of Diabetes, the Obesity Society,
the Endocrine Society, the Royal College of Physicians and Surgeons of Canada and
Edinburgh, and the American Federation for Clinical Research.
He has written about 200 original articles and participated as a co-author of more than
100 invited articles and book chapters. His current clinical research interests involve
the study of new therapies for type 1 and type 2 diabetes and obesity. Basic science
interests include study of the metabolic and ca<strong>rd</strong>iovascular effects of human muscle
and adipose tissue secretory products, signal interactions between skeletal muscle
and adipose tissue and defects of insulin signal transduction in these tissues of obese
and type 2 diabetic patients.
At this symposium, Professor Henry will give a presentation on recent research trends,
changes in treatment and prospects on diabetes with a title of “New agents in
development for therapy of type 2 diabetes”.